Cargando…
Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report
RATIONALE: Anti-IgLON5 disease was first described as a progressive antibody-associated encephalopathy, with multiple non-specific clinical symptoms including sleep dysfunction, bulbar symptoms, progressive supranuclear palsy-like syndrome, cognitive impairment, and a variety of movement disorders....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850656/ https://www.ncbi.nlm.nih.gov/pubmed/33530233 http://dx.doi.org/10.1097/MD.0000000000024384 |
_version_ | 1783645481785622528 |
---|---|
author | Pi, Yan Zhang, Li-li Li, Jing-cheng |
author_facet | Pi, Yan Zhang, Li-li Li, Jing-cheng |
author_sort | Pi, Yan |
collection | PubMed |
description | RATIONALE: Anti-IgLON5 disease was first described as a progressive antibody-associated encephalopathy, with multiple non-specific clinical symptoms including sleep dysfunction, bulbar symptoms, progressive supranuclear palsy-like syndrome, cognitive impairment, and a variety of movement disorders. This newly discovered disease presents with unremarkable or unspecific brain magnetic resonance imagings (MRI), and have poor responsiveness to immunotherapy. PATIENT CONCERNS: In this case, a 37-year-old man presented with 4-day history of gait instability, dysarthria, and oculomotor abnormalities. The initial neurologic examination revealed mild unsteady gait, subtle dysarthria, and left abducent paralysis. DIAGNOSIS: The patient was diagnosed with anti-IgLON5 disease, based on clinical features and positive anti-IgLON5 antibodies in serum. INTERVENTIONS: Initially, the patient was treated with high dosages of methylprednisolone and immunoglobulins. Outcomes: The symptoms of patient rapidly improved after high-dose intravenous methylprednisolone and immunoglobulins. CONCLUSIONS: In this paper, we report a new case of anti-IgLON5 disease with major symptoms of gait instability, dysarthria, and oculomotor abnormalities, with distinctive brain MRI findings, and responsive to immunotherapy. |
format | Online Article Text |
id | pubmed-7850656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-78506562021-02-02 Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report Pi, Yan Zhang, Li-li Li, Jing-cheng Medicine (Baltimore) 5300 RATIONALE: Anti-IgLON5 disease was first described as a progressive antibody-associated encephalopathy, with multiple non-specific clinical symptoms including sleep dysfunction, bulbar symptoms, progressive supranuclear palsy-like syndrome, cognitive impairment, and a variety of movement disorders. This newly discovered disease presents with unremarkable or unspecific brain magnetic resonance imagings (MRI), and have poor responsiveness to immunotherapy. PATIENT CONCERNS: In this case, a 37-year-old man presented with 4-day history of gait instability, dysarthria, and oculomotor abnormalities. The initial neurologic examination revealed mild unsteady gait, subtle dysarthria, and left abducent paralysis. DIAGNOSIS: The patient was diagnosed with anti-IgLON5 disease, based on clinical features and positive anti-IgLON5 antibodies in serum. INTERVENTIONS: Initially, the patient was treated with high dosages of methylprednisolone and immunoglobulins. Outcomes: The symptoms of patient rapidly improved after high-dose intravenous methylprednisolone and immunoglobulins. CONCLUSIONS: In this paper, we report a new case of anti-IgLON5 disease with major symptoms of gait instability, dysarthria, and oculomotor abnormalities, with distinctive brain MRI findings, and responsive to immunotherapy. Lippincott Williams & Wilkins 2021-01-29 /pmc/articles/PMC7850656/ /pubmed/33530233 http://dx.doi.org/10.1097/MD.0000000000024384 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 5300 Pi, Yan Zhang, Li-li Li, Jing-cheng Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report |
title | Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report |
title_full | Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report |
title_fullStr | Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report |
title_full_unstemmed | Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report |
title_short | Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report |
title_sort | anti-iglon5 disease with distinctive brain mri findings responding to immunotherapy: a case report |
topic | 5300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850656/ https://www.ncbi.nlm.nih.gov/pubmed/33530233 http://dx.doi.org/10.1097/MD.0000000000024384 |
work_keys_str_mv | AT piyan antiiglon5diseasewithdistinctivebrainmrifindingsrespondingtoimmunotherapyacasereport AT zhanglili antiiglon5diseasewithdistinctivebrainmrifindingsrespondingtoimmunotherapyacasereport AT lijingcheng antiiglon5diseasewithdistinctivebrainmrifindingsrespondingtoimmunotherapyacasereport |